G1 Therapeutics to Participate in Two Upcoming September Conferences

Rhea-AI Summary

G1 Therapeutics, a commercial-stage oncology company, will participate in two virtual investor conferences in September 2021. On September 10, G1 will attend the Citi 16th Annual BioPharma Virtual Conference, which does not include a webcast. On September 13, CEO Jack Bailey will present at the H.C. Wainwright 23rd Annual Global Investment Conference, with a webcast available on demand. G1 Therapeutics focuses on developing therapies to improve cancer patients' lives, with a clinical pipeline including COSELA™ for various solid tumors.

News Market Reaction – GTHX

-1.04%

-1.04% Session move

In the trading session that priced this news, GTHX declined 1.04%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in September.

• On September 10, 2021, G1 will participate in the Citi 16th Annual BioPharma Virtual Conference. There is no webcast associated with this conference.
  
  
• On September 13, 2021, G1’s Chief Executive Officer Jack Bailey will present at the H.C. Wainwright 23rd Annual Global Investment Conference. This will be available on demand beginning the morning of September 13, 2021. The webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.
  

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com

 

FAQ

When is GTHX participating in the Citi 16th Annual BioPharma Virtual Conference?

GTHX will participate in the Citi 16th Annual BioPharma Virtual Conference on September 10, 2021.

Who will present GTHX at the H.C. Wainwright 23rd Annual Global Investment Conference?

CEO Jack Bailey will present GTHX at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021.

Where can I access the webcast for GTHX's presentation on September 13?

The webcast for GTHX's presentation on September 13 can be accessed on their Events & Presentations page.

What is the focus of G1 Therapeutics in oncology?

G1 Therapeutics focuses on developing next-generation therapies for cancer, including their first product, COSELA™.

What types of cancers is G1 Therapeutics targeting with COSELA?

G1 Therapeutics is evaluating COSELA in various solid tumors, including colorectal, breast, lung, and bladder cancers.